Searchable abstracts of presentations at key conferences in endocrinology

ea0056p654 | Endocrine tumours and neoplasia | ECE2018

Fibroblast-kinome silencing to identifies putative mediator of Triple-negative breast cancer (TNBC) invasion

Gagliano Teresa , Vella Viviana , Bienkowska Kamila , Ditsiou Angeliki , Giamas Georgios

Kinases represent a main therapeutic targets in cancer treatment as their impairing is related to tumor growth and progression. Despite the increasing evidence that tumor microenvironment (TME) signaling influences the behavior of surrounding cancer epithelial cells, still little is known about what changes in stromal cells influence tumor cellsÂ’ behavior. TNBC patients are still lacking an effective therapy, as not much is known about the biology of this BC tumor subtype...

ea0063p38 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Influence of Tumor Microenviroment in response modulation to treatment in human BP-NENs

Bresciani Giulia , Ditsiou Angeliki , Cilibrasi Chiara , Vella Viviana , Giamas Georgios , Zatelli Maria Chiara , Gagliano Teresa

Introduction: Broncho-Pulmonary Neoplasms (BP-NENs) are rare neoplasms arising from neuroendocrine cells of the respiratory epithelium. Since previous studies in our lab have demonstrated the efficacy ofEverolimus, approved for BP-NENs treatment, and Dinaciclib, a Cyclins and CdKs inhibitor, on monolayer system we have investigated if a more complex tumour system could generate a change in drugs effects and cell resistance. Therefore, through the use of 3D culture model, we ha...

ea0063p464 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

EGFR and IGF1R affect Sunitinib activity: novel targets for Broncho-Pulmonary Neuroendocrine Neoplasm treatment

Bresciani Giulia , Ditsiou Angeliki , Cilibrasi Chiara , Vella Viviana , Rea Federico , Schiavon Marco , Cavallesco Narciso Giorgio , Giamas Georgios , Zatelli Maria Chiara , Gagliano Teresa

Background: Available medical treatments for Broncho-Pulmonary Neuroendocrine Neoplasm (BP-NENs) derived from clinical trials are not specific for the management of this malignancy. Sunitinib, a multi-receptor tyrosine-kinases (RTKs) inhibitor, mainly described as VEGFR inhibitor, has shown its efficacy in Pancreatic NENs but there are not available data about its action in BP-NENs. Our aim was to understand the effects of RTKs inhibition promoted by Sunitinib in order to eval...